WhatsApp Medicine and the Unfair Advantage of Starting Where Healthcare Actually Happens

DEC 17, 2025 • PAID

DISCLAIMER: The views and opinions expressed in this essay are solely my own
do not reflect the views, opinions, or positions of my employer.

If you are interested in joining my generalist healthcare angel syndicate, reach o
trey@onhealthcare.tech or send me a DM. Accredited investors only.

ABSTRACT

Leona Health raised $14 million in seed funding from Andreessen Horowitz to b
AI-powered practice management infrastructure on top of WhatsApp, starting i
Latin America. This essay examines why the company's approach represents a
fundamental rethinking of healthcare software distribution, how messaging-firs
architecture creates defensibility through data network effects, and what this m
for healthcare AI investment opportunities in emerging markets. Key topics incl
the structural advantages of building on existing communication platforms, the
economics of AI-native medical software, regulatory arbitrage opportunities in I
American markets, and lessons for angels evaluating similar business models in
geographies.

TABLE OF CONTENTS

The Problem with Starting Where Doctors Aren’t

Here’s what most American healthcare software companies get wrong from day c They build products assuming doctors want to change their behavior, that clinic will adopt new tools if those tools are better, and that you can convince healthca providers to add another login to their already overwhelming stack of software. ' assumption kills most healthcare startups before they even understand why they dying.

Leona Health’s seed funding announcement from a16z caught my attention not because of the fourteen million dollars or the pedigree of the lead investor, but because the company is doing something that seems obvious in hindsight but re genuine insight to see in the first place. They’re building medical practice management software that plugs into the communication tool doctors already us eight hours a day. In Latin America, that tool is WhatsApp, and the penetration numbers make American healthcare IT adoption rates look like a joke.

The typical healthcare software pitch goes something like this: doctors need bet tools, we built better tools, therefore doctors will use our tools. The logical chai seems sound until you realize that doctors already have forty three different logi

their EHR vendor charges them thousands per month for basic functionality, an last thing anyone wants is to learn another interface. This is why healthcare soft sales cycles take forever, why adoption rates disappoint even after expensive implementations, and why so many promising health IT companies end up sellin hospital IT departments instead of directly to providers.

Leona's approach flips this entirely. Instead of asking doctors to come to their platform, they built their platform where patients already live. In Brazil, Mexico Argentina, and across Latin America, WhatsApp isn't just a messaging app. It's l patients communicate with doctors, how they schedule appointments, how they health questions, and how they actually access care. The usage patterns are alrea there, the behavioral change already happened, and now Leona is adding the laye makes all of this actually work for medical practice.

The company's AI handles patient intake, appointment scheduling, medical hist collection, and documentation. Patients continue using WhatsApp exactly as the always have, sending messages to their doctors. But on the doctor's side, instead managing hundreds of chaotic WhatsApp threads, they receive and manage all t communication through Leona's mobile app. The system categorizes messages b urgency, suggests responses, enables team delegation, and structures unstructur conversations into medical records. From the patient's perspective nothing chan but the doctor's workflow becomes dramatically more efficient.

Why WhatsApp Is Healthcare Infrastructure in Latin America

Let's talk numbers because the penetration rates actually matter here. WhatsAp ninety nine percent smartphone penetration in Brazil. Not ninety nine percent o people who use messaging apps, ninety nine percent of people who own smartph have WhatsApp installed. In Mexico and Argentina, it's similar. The pattern hol across the region with over ninety two percent penetration in Latin America ove This isn't like the US where messaging is fragmented across iMessage, SMS, Fac

Messenger, and a dozen other platforms. In Latin America, WhatsApp is the communication layer for basically everything.

More importantly for healthcare, ninety five percent of doctors in Latin America report using WhatsApp to run their practice. Not because some vendor convinced them to adopt it, not because their hospital IT department implemented it, but because their patients demanded it and the barrier to entry was zero. A patient sends a WhatsApp message, the doctor responds, and suddenly you have a doctor-patient communication channel that bypasses all the expensive patient portal software that US health systems spent millions implementing and that basically nobody uses.

This existing behavior creates what I'd call negative distribution cost. Leona doesn't need to convince doctors to change their workflow, doesn't need to overcome adoption resistance, doesn't need to spend years building integrations with existing EHR systems. The doctors' patients are already on WhatsApp, already managing their healthcare through messaging, already dealing with the chaos of unstructured patient conversations. Leona is just making that existing workflow functional instead of overwhelming.

The contrast with US healthcare IT is stark. American EHR vendors spent decades and billions of dollars creating walled gardens, and now every new healthcare software company needs to either integrate with those systems or convince doctors to use something completely separate. The integration path is expensive and slow, the separate system path requires massive behavior change, and both approaches mean your go-to-market timeline is measured in years not months.

Leona's path is different because WhatsApp already did the hard work of behavior change. The platform is trusted, ubiquitous, and central to how healthcare actually happens in these markets. Building infrastructure that sits on top of WhatsApp means you inherit all the distribution advantages that would normally take a decade to build yourself.

The AI Layer That Makes Messaging Medical

The really interesting technical challenge here is turning unstructured WhatsAp conversations into structured medical data, and doing it in real time without bre the user experience. This is where the AI matters and where Leona's product is actually defensible beyond just being first to market on WhatsApp.

Think about what happens in a typical doctor-patient WhatsApp conversation. A patient sends messages over several hours describing symptoms, the doctor asks follow-up questions, maybe the patient sends photos or voice messages, there's b and forth about scheduling, discussion of medications, questions about side effe and eventually some kind of treatment plan. All of this is valuable medical information but it's completely unstructured, mixed with scheduling logistics, a spread across dozens of messages that might arrive at random times.

Leona's AI needs to extract signal from that noise in real time. It needs to unders medical context in Spanish and Portuguese, recognize when a conversation threa represents a meaningful clinical encounter versus just administrative scheduling structure that information into documentation that meets local regulatory requirements, and do all of this while maintaining the conversational flow that r WhatsApp feel natural to users. The system categorizes messages by urgency so doctors can triage effectively, suggests draft responses to speed up communicati and enables team delegation so other staff can handle routine questions.

The technical architecture here is AI-native in a way that legacy healthcare softw can't replicate by bolting AI onto existing systems. Instead of starting with struc forms and database schemas and then trying to layer natural language processing top, Leona started with unstructured conversations and built the AI to create structure only where and when it's needed. This means the system gets better as conversations flow through it, the models improve with more medical context, a data network effects compound over time.

This is also where the moat gets built. Every patient conversation that flows thro Leona's system teaches the AI more about how doctors and patients actually communicate about health, what symptoms matter, how to recognize urgent situ versus routine questions, and how to structure that information for downstream

Competitors can't replicate this data advantage without similar conversation vol and they can't get that volume without building similar distribution, which brin back to the WhatsApp infrastructure advantage.

The AI also handles the economics in a way that makes the unit economics actua work. Traditional practice management software requires significant human lab input data, manage scheduling, handle billing, and maintain records. Leona auto most of that labor through AI, which means the cost to serve each additional doc dramatically lower than traditional software. Doctors using the system report sa two to three hours per day. This creates leverage that allows for more aggressive pricing, faster expansion, and better margins at scale.

Economics of Zero Distribution Cost

Let's dig into the financial model because this is where things get really interest for investors. Traditional healthcare software has brutal economics in the early s You need a big sales team to navigate long sales cycles, you need implementatior teams to get customers live, you need ongoing support to handle all the integrati issues, and you need to price high enough to cover all of that overhead. This usu means six figure annual contracts, twelve month sales cycles, and burn rates that require massive venture funding to survive until you reach scale.

Leona's model is completely different because of the zero distribution cost dyna Doctors can start using the service immediately, there's no implementation requ no integration work, no training needed. Patients keep using WhatsApp exactly before, doctors download Leona's app and connect it to their WhatsApp, and the system starts working. This means the path from first contact to paying custome be measured in days not months, and the cost to acquire each customer is driven marketing spend not sales infrastructure.

The implications cascade through the entire business model. With fast onboardi and low acquisition cost, you can afford to price aggressively to drive adoption. V AI handling most of the operational work, your cost to serve each customer stays even as you scale. With product usage happening through patients' existing

WhatsApp behavior, you inherit viral dynamics where satisfied patients naturall drive more doctors to adopt because those doctors are already getting WhatsApp messages from patients who expect the same level of service.

This creates a growth model that looks more like consumer software than traditi healthcare IT. You can grow revenue faster than headcount, you can expand geographically without building local sales teams, and you can reach profitabilit much smaller scale than competitors who need massive sales organizations. For stage investors, this means capital efficiency that's rare in healthcare software ar path to outcomes that doesn't require hundreds of millions in funding.

The pricing flexibility also matters strategically. Because Leona's cost structure i different from traditional practice management software, they can underprice competitors dramatically and still have better unit economics. This isn't a race t bottom on price, it's structural cost advantage that allows for strategic pricing decisions that would be impossible with a traditional sales-heavy model.

There's also interesting dynamics around payment flows. In many Latin America markets, patients pay doctors directly rather than going through insurance intermediaries. This means Leona can potentially sit in the middle of payment processing, taking a small percentage of transactions in addition to subscription revenue. If they execute on this, the revenue per customer could be significantly higher than pure software fees while still being cheaper for doctors than existing payment processing solutions.

Regulatory Arbitrage and Market Entry Timing

One of the questions that comes up with any healthcare AI company is regulator and Leona's Latin American focus creates some interesting dynamics here that a worth understanding if you're evaluating similar opportunities.

The regulatory environment for medical AI in Latin America is less developed th the US or Europe, which creates both opportunity and risk. The opportunity is t

Leona can move faster, iterate more aggressively, and prove out their model befo facing the kind of regulatory scrutiny that would slow them down in more devel markets. The risk is that regulations could tighten in ways that make their curre approach more difficult, or that early missteps could invite regulatory attention hurts the entire category.

My read is that the timing actually favors Leona here. Latin American regulators watching how AI gets deployed in healthcare in the US and Europe, and they're generally trying to enable innovation rather than restrict it. The political dynam favor solutions that improve healthcare access and efficiency, especially tools tha private practice doctors serve more patients. As long as Leona stays focused on augmenting doctor decision-making rather than replacing it, and as long as they careful about data privacy and security, the regulatory path seems manageable. Countries like Brazil have data protection regimes like LGPD that require prop handling of consent, auditability, and role-based access, but these are solvable problems for a well-designed system.

There's also strategic timing around market maturity. Latin American healthcar systems are still developing their digital infrastructure, which means there's less legacy technology to work around and more willingness to adopt new approache Doctors who might resist new software in the US because they're already locked established systems are more open to innovation in markets where the existing solutions are less entrenched.

The company's decision to start in Latin America rather than the US also creates interesting optionality for future expansion. If they prove the model in markets distribution is easier and regulation is lighter, they build the data moat and operational experience that makes expansion to harder markets more feasible. T might be the eventual prize in terms of market size, but going there first would meant years of grinding through difficult sales cycles and regulatory processes b proving product-market fit.

This geographic sequencing strategy is something more healthcare startups shou consider. The instinct is always to go after the biggest market first, but that ignc

the reality that the biggest markets often have the highest barriers to entry. Star where you can win fast and build defensibility, then using that success to fund expansion into harder markets, is often a better path even if it feels less ambitiou first.

Data Network Effects in Medical Messaging

The real long-term moat here is the data network effects that come from being t infrastructure layer for doctor-patient messaging at scale. Every conversation th flows through Leona's system makes their AI smarter, their automation better, a their product more valuable to the next doctor who adopts it.

Think about what this looks like five years out if Leona executes. They'll have processed millions of doctor-patient conversations across dozens of specialties a hundreds of clinical scenarios. Their AI will understand the natural progression diseases based on how symptoms get reported in unstructured conversations. Th know which treatment approaches lead to patients reporting better outcomes in follow-up messages. They'll have learned the early warning signs of complicatio based on subtle changes in how patients describe their condition.

This is medical knowledge that doesn't exist in structured form anywhere else. E data captures visits and billing codes but misses all the patient-reported informa between visits. Research studies are clean and controlled but don't reflect how medicine actually gets practiced in the real world. Leona's dataset will be messy unstructured but will represent the actual practice of medicine at massive scale.

The network effects compound in interesting ways. As more doctors use the plat the AI gets better at medical reasoning, which makes the product more valuable, which drives more adoption. As more specialties get represented, the system can with cross-specialty consultation and referral management. As more patients use Leona can start building longitudinal health records that follow patients across different providers.

There's also interesting dynamics around what you can build on top of this infrastructure once you have the messaging layer locked in. Population health analytics, predictive models for patient deterioration, automated care coordinati supply chain management for medical practices, integration with labs and pharmacies. All of these become easier to build when you already have the docto patient communication as your foundation.

The key thing is that this moat is time-based and scale-based in a way that's diff to replicate. A competitor who starts later has worse AI, which means worse pro which means slower adoption, which means even worse AI relative to Leona. The flywheel creates increasing returns to scale that make the market tend toward w take-most dynamics.

What This Means for Angels

For angels evaluating opportunities in healthcare AI or emerging market health Leona's approach offers several lessons worth internalizing.

First, distribution matters more than product quality in healthcare software, and best distribution strategy is usually building on top of infrastructure that alread adoption. Too many healthcare startups die trying to convince doctors to change behavior when they should be looking for places where the behavior change alre happened and the infrastructure is just missing the intelligence layer.

Second, AI-native architecture creates different economics than bolting AI onto systems. Companies that start with unstructured data and use AI to create struc only where needed can scale faster and cheaper than companies that start with r data models and try to add flexibility later. This matters for unit economics, capi efficiency, and ultimate defensibility.

Third, emerging markets often offer better entry points for healthcare innovatio the US, not because the market opportunity is bigger but because the barriers to are lower and the path to proving product-market fit is faster. The instinct to sta the US because that's where the money is often leads to years of grinding throug

sales cycles when you could have been building a real business in markets where adoption happens faster.

Fourth, the combination of messaging infrastructure and medical AI creates dat network effects that are hard to replicate and that compound over time. This is t kind of moat that justifies venture-scale outcomes, and it's particularly powerful markets where existing medical data is fragmented and low quality.

For angels specifically, the challenge with opportunities like Leona is that by the they're raising seed rounds from a16z with fourteen million dollars, the earliest opportunity is gone. The question is how to find similar opportunities earlier, ar answer usually involves looking for founders who deeply understand a specific geography or vertical and who are building on top of existing infrastructure rath than trying to create new behavior from scratch.

The pattern to look for is products that feel obvious in hindsight but required re insight to see initially. Doctors using WhatsApp for patient communication seer obvious once you understand Latin American messaging behavior, but it took someone actually embedded in those markets to see the opportunity and execute The best angel investments often have this quality where the thesis seems clear a the fact but wasn't obvious to outsiders before someone built it.

There's also a broader lesson about where healthcare innovation is likely to happ over the next decade. The combination of ubiquitous smartphones, capable AI, a regulatory environments that are still figuring out how to govern these technolo creates opportunities in markets that US investors traditionally ignore. Latin America, Southeast Asia, Africa, and India all have massive populations, growing middle classes, and healthcare systems that are still being built. Companies that real problems in these markets with capital-efficient models can build very large businesses while US-focused competitors are still trying to navigate enterprise s cycles.

The Leona model also suggests that the future of medical software might look le traditional enterprise software and more like infrastructure that sits invisibly

underneath existing communication platforms. Instead of standalone applicatio with their own interfaces and workflows, we might see intelligence layers that m existing tools work better. This has implications for how we evaluate healthcare investments and where we look for the next generation of category-defining companies.

For angels building a healthcare portfolio, exposure to emerging market health t and AI-native medical software seems increasingly important. These aren't niche categories anymore, they're where some of the most interesting innovation is happening and where the path to large outcomes might actually be faster than traditional US healthcare software.

The Leona story is still early and execution risk remains high. Building across multiple Latin American markets means navigating different regulatory environments, payment systems, and healthcare delivery models. Maintaining AI quality as the system scales and handles more edge cases will be technically challenging. Competition from local players and eventually from well-funded US companies copying the model is inevitable. The team is only thirteen people spli between Mexico City and Silicon Valley, which means they'll need to scale hiring while maintaining quality.

But the core insight about building on top of existing communication infrastruc in markets where that infrastructure is already central to healthcare delivery see sound. The economics work, the data network effects are real, and the path to sc clearer than most healthcare software businesses. Whether Leona specifically su or not, the model they're pursuing offers valuable lessons for investors trying to understand where healthcare innovation is heading and what patterns to look fo the next generation of winning companies.

← Previous

Nex

Discussion about this post

Comments Restacks

Write a comment...